中国重症肌无力诊断和治疗指南(2020版)

2021-01-26 中国免疫学会神经免疫分会 中国神经免疫学和神经病学杂志.2021.28(1):1-12.

2015年《中华神经科杂志》发布了第1版中国重症肌无力诊断和治疗指南。时隔5年,在重症肌无力治疗方面积累了更多循证医学的证据,迫切需要更新指南来指导临床实践。因此,中国免疫学会神经免疫分会基于近5年国

中文标题:

中国重症肌无力诊断和治疗指南(2020版)

发布日期:

2021-01-26

简要介绍:

2015年《中华神经科杂志》发布了第1版中国重症肌无力诊断和治疗指南。时隔5年,在重症肌无力治疗方面积累了更多循证医学的证据,迫切需要更新指南来指导临床实践。因此,中国免疫学会神经免疫分会基于近5年国内外文献中的最新证据,参考相关国际指南,反复讨论,在对中国重症肌无力诊治指南(2015)更新修订的基础上编写了本指南。新指南采用MGFA临床分型替代Osserman分型,旨在对疾病严重程度进行量化评估;提出重症肌无力亚组分类,指导精准化治疗;对治疗目标进行了定义;针对胸腺切除,利妥昔单抗、依库珠单抗等生物制剂的应用,眼肌型重症肌无力早期免疫抑制治疗以及免疫检查点抑制剂治疗相关重症肌无力等方面提出了新的建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国重症肌无力诊断和治疗指南_2020版_常婷.pdf)] GetToolGuiderByIdResponse(projectId=1, id=849c01c0020ae48e, title=中国重症肌无力诊断和治疗指南(2020版), enTitle=, guiderFrom=中国神经免疫学和神经病学杂志.2021.28(1):1-12., authorId=0, author=, summary=2015年《中华神经科杂志》发布了第1版中国重症肌无力诊断和治疗指南。时隔5年,在重症肌无力治疗方面积累了更多循证医学的证据,迫切需要更新指南来指导临床实践。因此,中国免疫学会神经免疫分会基于近5年国, cover=https://img.medsci.cn/2021131/1612084537755_2020535.jpg, journalId=0, articlesId=null, associationId=152, associationName=中国免疫学会神经免疫分会, associationIntro=null, copyright=0, guiderPublishedTime=Tue Jan 26 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2015年《中华神经科杂志》发布了第1版中国重症肌无力诊断和治疗指南。时隔5年,在重症肌无力治疗方面积累了更多循证医学的证据,迫切需要更新指南来指导临床实践。因此,中国免疫学会神经免疫分会基于近5年国内外文献中的最新证据,参考相关国际指南,反复讨论,在对中国重症肌无力诊治指南(2015)更新修订的基础上编写了本指南。新指南采用MGFA临床分型替代Osserman分型,旨在对疾病严重程度进行量化评估;提出重症肌无力亚组分类,指导精准化治疗;对治疗目标进行了定义;针对胸腺切除,利妥昔单抗、依库珠单抗等生物制剂的应用,眼肌型重症肌无力早期免疫抑制治疗以及免疫检查点抑制剂治疗相关重症肌无力等方面提出了新的建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=10253, tagName=重症肌无力)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=10253, guiderKeyword=重症肌无力, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9168, appHits=714, showAppHits=0, pcHits=2057, showPcHits=8452, likes=7, shares=54, comments=34, approvalStatus=1, publishedTime=Sun Jan 31 17:51:13 CST 2021, publishedTimeString=2021-01-26, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Jan 31 17:15:44 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 21:48:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国重症肌无力诊断和治疗指南_2020版_常婷.pdf)])
中国重症肌无力诊断和治疗指南_2020版_常婷.pdf
下载请点击:
评论区 (27)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2115649, encodeId=b2612115649c9, content=参考学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef68112305, createdName=ms1000000439125996, createdTime=Tue Feb 21 09:36:01 CST 2023, time=2023-02-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2089697, encodeId=0aa5208969ee3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48122453186, createdName=医学僧来报道, createdTime=Thu Sep 22 08:26:10 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184126, encodeId=ad22118412664, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61db6465365, createdName=ms6000001502420026, createdTime=Fri Jan 14 07:34:35 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069399, encodeId=d29c1069399b9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9EU2n1Rc4FEr2QicklnU0GaH4ouOn57Reu8dOL6vKyzOejT2H82xic4t56PmemlJxUC1eEwicz3A1F30LYDXB4iazw/132, createdBy=5ffa2447732, createdName=JXYJXY, createdTime=Thu Nov 11 22:29:34 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064112, encodeId=ae67106411257, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ce5256023, createdName=147f08e8m36暂无昵称, createdTime=Tue Oct 26 15:36:31 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2023-02-21 ms1000000439125996 来自广东省

    参考学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2115649, encodeId=b2612115649c9, content=参考学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef68112305, createdName=ms1000000439125996, createdTime=Tue Feb 21 09:36:01 CST 2023, time=2023-02-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2089697, encodeId=0aa5208969ee3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48122453186, createdName=医学僧来报道, createdTime=Thu Sep 22 08:26:10 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184126, encodeId=ad22118412664, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61db6465365, createdName=ms6000001502420026, createdTime=Fri Jan 14 07:34:35 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069399, encodeId=d29c1069399b9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9EU2n1Rc4FEr2QicklnU0GaH4ouOn57Reu8dOL6vKyzOejT2H82xic4t56PmemlJxUC1eEwicz3A1F30LYDXB4iazw/132, createdBy=5ffa2447732, createdName=JXYJXY, createdTime=Thu Nov 11 22:29:34 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064112, encodeId=ae67106411257, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ce5256023, createdName=147f08e8m36暂无昵称, createdTime=Tue Oct 26 15:36:31 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2022-09-22 医学僧来报道

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2115649, encodeId=b2612115649c9, content=参考学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef68112305, createdName=ms1000000439125996, createdTime=Tue Feb 21 09:36:01 CST 2023, time=2023-02-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2089697, encodeId=0aa5208969ee3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48122453186, createdName=医学僧来报道, createdTime=Thu Sep 22 08:26:10 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184126, encodeId=ad22118412664, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61db6465365, createdName=ms6000001502420026, createdTime=Fri Jan 14 07:34:35 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069399, encodeId=d29c1069399b9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9EU2n1Rc4FEr2QicklnU0GaH4ouOn57Reu8dOL6vKyzOejT2H82xic4t56PmemlJxUC1eEwicz3A1F30LYDXB4iazw/132, createdBy=5ffa2447732, createdName=JXYJXY, createdTime=Thu Nov 11 22:29:34 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064112, encodeId=ae67106411257, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ce5256023, createdName=147f08e8m36暂无昵称, createdTime=Tue Oct 26 15:36:31 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2022-01-14 ms6000001502420026

    很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2115649, encodeId=b2612115649c9, content=参考学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef68112305, createdName=ms1000000439125996, createdTime=Tue Feb 21 09:36:01 CST 2023, time=2023-02-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2089697, encodeId=0aa5208969ee3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48122453186, createdName=医学僧来报道, createdTime=Thu Sep 22 08:26:10 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184126, encodeId=ad22118412664, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61db6465365, createdName=ms6000001502420026, createdTime=Fri Jan 14 07:34:35 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069399, encodeId=d29c1069399b9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9EU2n1Rc4FEr2QicklnU0GaH4ouOn57Reu8dOL6vKyzOejT2H82xic4t56PmemlJxUC1eEwicz3A1F30LYDXB4iazw/132, createdBy=5ffa2447732, createdName=JXYJXY, createdTime=Thu Nov 11 22:29:34 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064112, encodeId=ae67106411257, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ce5256023, createdName=147f08e8m36暂无昵称, createdTime=Tue Oct 26 15:36:31 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2021-11-11 JXYJXY

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2115649, encodeId=b2612115649c9, content=参考学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef68112305, createdName=ms1000000439125996, createdTime=Tue Feb 21 09:36:01 CST 2023, time=2023-02-21, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2089697, encodeId=0aa5208969ee3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48122453186, createdName=医学僧来报道, createdTime=Thu Sep 22 08:26:10 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184126, encodeId=ad22118412664, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61db6465365, createdName=ms6000001502420026, createdTime=Fri Jan 14 07:34:35 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069399, encodeId=d29c1069399b9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9EU2n1Rc4FEr2QicklnU0GaH4ouOn57Reu8dOL6vKyzOejT2H82xic4t56PmemlJxUC1eEwicz3A1F30LYDXB4iazw/132, createdBy=5ffa2447732, createdName=JXYJXY, createdTime=Thu Nov 11 22:29:34 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064112, encodeId=ae67106411257, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ce5256023, createdName=147f08e8m36暂无昵称, createdTime=Tue Oct 26 15:36:31 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2021-10-26 147f08e8m36暂无昵称

    不错

    0

拓展阅读

2011年中国重症肌无力诊断和治疗专家共识

中华医学会神经病学分会神经免疫学组 · 2011-09-01

2012 MGFA美国重症肌无力临床试验建议

美国重症肌无力基金会(MGFA,Myasthenia Gravis Foundation of America) · 2012-06-30

2014 EFNS/ENS眼肌型重症肌无力治疗指南

欧洲神经科学协会联盟(EFNS,European Federation of Neurological Societies) · 2014-01-28

中国重症肌无力诊断和治疗指南2015

中华医学会神经病学分会神经免疫学组 · 2016-04-25

2016 重症肌无力的管理国际共识指南(全文)

美国重症肌无力基金会(MGFA,Myasthenia Gravis Foundation of America) · 2016-06-29

2016 重症肌无力的管理国际共识指南(执行摘要)

美国重症肌无力基金会(MGFA,Myasthenia Gravis Foundation of America) · 2016-07-13